300765 CSPC Innovation Pharmaceutical
- 29.28
- +0.51+1.77%
CSPC Innovation Pharmaceutical News
New Novus: Independent financial adviser\'s inspection opinion on the transaction in accordance with section 4 of the “Supervisory Guidelines for Listed Companies No. 9 - Regulatory Requirements for Listed Companies to Plan and Implement Major Asset Restructurings”
New Novus: Independent financial adviser\'s opinion on the company\'s stock price fluctuations before the transaction information was released
New Novus: CSPC Innovative Pharmaceutical Co., Ltd. issues shares and pays cash to purchase assets and raise supporting capital and related transactions (draft)
New Novus: The Board\'s explanation on the purchase and sale of assets within 12 months prior to this transaction
New Novus: Independent financial advisors have no verification opinions on whether the entities involved in this transaction are prohibited from participating in the major asset restructuring situation of listed companies in accordance with section 12 of the “Guidelines for the Supervision of Listed Companies No. 7 - Supervision of Abnormal Stock Transactions Related to Major Asset Restructurings of Listed Companies”
New Novus: Announcement on progress plans after issuing shares and paying cash to purchase assets and raise supporting capital and related transactions
New Novus: Independent financial adviser\'s opinion on whether the underlying assets of this transaction have been used by its shareholders and related parties for non-operating purposes
New Novus: Independent Financial Adviser\'s Independent Financial Advisory Report on the Issuance of Shares by Shiyao Innovative Pharmaceutical Co., Ltd. and the payment of cash to purchase assets and raise supporting capital and related transactions
New Novus: Independent Financial Adviser\'s Verification Opinions on Complying with the Relevant Regulations of the “Opinions on Strengthening the Prevention and Control of the Risks of Employing Third Parties, etc. by Securities Companies in Investment Banking Businesses”
New Novus: Announcement of CSPC Pharmaceutical Innovation Pharmaceutical Co., Ltd. on the acceptance of financial support and related transactions by its holding subsidiary
New Novus: Explanation of the Board of Directors on the diluted immediate return situation, correction measures and commitments of this transaction
New Novus: Board Statement on the Development and Implementation of the Insider Information Insider Registration System
New Novus: Independent Financial Adviser\'s Opinions on the Formulation and Implementation of the Insider Information Insider Registration System for this transaction
New Novus: Commitments issued by independent financial advisors based on full due diligence and core
New Novus: 1. General Risk Warning Notice on Issuing Shares and Paying Cash to Purchase Assets and Raising Supporting Funds and Related Transactions
New Novus: Explanation of the Board of Directors that entities involved in this transaction are not allowed to participate in the major asset restructuring of listed companies in accordance with Article 12 of the “Supervisory Guidelines for Listed Companies No. 7 - Supervision of Abnormal Stock Transactions Related to Major Asset Restructuring of Listed Companies” and Section 30 of the “Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 8 - Major Asset Restructurings (2023 Revision)”
New Novus: Legal Opinion of Beijing Junzejun Law Firm on the Issuance of Shares by Shiyao Innovative Pharmaceutical Co., Ltd. and the payment of cash to purchase assets and raise supporting capital and related transactions
New Novus: Independent financial adviser\'s opinion on the verification that this transaction complies with the relevant regulations of GEM listed companies
New Novus: Beijing Junzejun Law Firm\'s Special Inspection Opinions on the Formulation and Implementation of the Insider Information Insider Registration System for Shiyao Innovative Pharmaceutical Co., Ltd. to issue shares and pay cash to purchase assets and raise supporting capital and related transactions
New Novus: Asset Evaluation Report for the Shareholders\' Equity Value Assessment Project of Shiyao Group Baike (Shandong) Biopharmaceutical Co., Ltd. involved in the project to issue shares and pay cash to purchase assets and raise supporting capital
Analysis
Price Target
No Data
No Data